<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309890</url>
  </required_header>
  <id_info>
    <org_study_id>Arabic OABSS- 7 items</org_study_id>
    <nct_id>NCT04309890</nct_id>
  </id_info>
  <brief_title>Arabic Translation and Validation of the (Overactive Bladder Symptom Score) OABSS</brief_title>
  <official_title>Validating 7-items Overactive Bladder Symptom Score (OABSS) Through Arabic Linguistic Version</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mutah University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mutah University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The English version of the Overactive Bladder Symptom Score (OABSS) questionnaire was
      translated to Arabic language. The questionnaire was validated by comparing the response to
      the questionnaire in a patient with Overactive Bladder (OAB) before and after providing
      treatment with antimuscarinics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>development and validation of Arabic version of the Overactive Bladder Symptom Score (OABSS) questionnaire</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">235</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arabic version of the Overactive Bladder Symptom Score Questionnaire</intervention_name>
    <description>All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study has included 235 patients, 152 (62.9%) females and 83 (37.1%) males.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than 20 years

          -  Had three months history of overactive bladder symptoms (urgency with or without
             incontinence and associated with frequency and nocturia).

        Exclusion Criteria:

          -  Active urinary tract infection.

          -  Predominant symptoms of urinary stress incontinence;

          -  Diabetes mellitus;

          -  Previous abdominal and pelvic (urological or gynecological gastrointestinal) surgery;

          -  Previous neurological disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mu'tah University</name>
      <address>
        <city>Karak</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mutah University</investigator_affiliation>
    <investigator_full_name>Fadi Sawaqed</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

